FABP5 and intrahepatic cholangiocarcinoma: Six studies with 603 patients revealed that FABP5 expression was more strongly associated with UICC in patients with HCC (OR = 2.920, 95% CI = 1.721, 4.953, p < 0.001, I2 = 0.0%) compared to those with digestive tract cancers, including GC, ESCC, and ICC (Table 3, Figure 3B).